News|Articles|December 4, 2025
Accelerate Next-Generation Bioconjugate Development through an Innovative Technology Platform
Author(s)WuXi XDC
The path to ADC success demands precision – from DAR optimization and linker stability to rigorous safety profiling! Discover how novel conjugation and payload-linker platform empowers the rational design of next-generation ADCs with enhanced therapeutic potential —improving efficacy, stability and safety.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Next-Generation Modalities Drive New Antibody Discovery
2
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
3
European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE
4
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
5